The sprawling opioid litigation confronting drug makers and distributors is likely to take years to resolve, but cost less than the infamous lawsuits that were filed against Big Tobacco and, not surprisingly, will hurt some companies more than others, a new credit analysis suggests.

For the moment, the litigation is still in the early stages and the first trials are not scheduled until September 2019. But despite the uncertainty, any potential settlement is expected to be “considerably lower” than the $206 billion deal reached with the four largest U.S. cigarette makers in 1998, according to analysts at S&P Global Ratings.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy